EBS - Emergent BioSolutions: Positive Outlook Despite Current Lawsuit

• EBS is currently being sued for a manufacturing error involving the mixing of ingredients, which may result in the loss of its COVID-19-related transactions.
• Currently holds material transactions involving COVID-19 and the US Government's Warp Speed Program, as well as AstraZeneca and Johnson & Johnson.
• A positive catalyst could reverse unfavorable sentiment, as EBS just initiated a Phase 3 clinical trial sponsored by the National Institutes of Health for COVID-19 hyperimmune globulin.
• According to a DCF study, EBS still has upside potential despite pricing in COVID-related contractual losses and forecasting revenue at 2018 levels.

For further details see: